Peak Actinium: The Ac-225 Scarcity Cliff - Free Extract
The targeted alpha therapy sector agrees actinium-225 is the binding constraint, and billions of acquisition value rest on that belief. This extract argues the belief is correct today and about to stop being correct, and that the market has not yet dated the turn.
What this report answers
- Is actinium-225 scarcity a permanent condition or a dated one?
- What happens to a scarcity premium when announced capacity lands before the demand that would absorb it?
- Why would supply and demand curves cross from the wrong side?
- What decides how much announced production capacity is actually usable?
- Where does defensibility move once volume stops being the moat?
- What does this mean for producers, developers and investors specifically?
~$8bn
of alpha-focused acquisitions since late 2023 that the extract says rest on the scarcity belief. It is the premise the analysis stress-tests, not one of its findings.
What the analysis establishes
A timing argument, not a collapse argument
The extract is careful about what it is claiming. It does not argue that actinium-225 becomes worthless or that scarcity was imagined. It argues the scarcity trade has an expiry date, that the date is earlier than production-asset valuations assume, and that the gap between those two things is where the mispricing sits.
The build-out against the demand curve
Two of the four exhibits set the announced capacity build-out against the demand that would have to absorb it, and identify the window where the two are furthest out of step. The extract describes what governs the timing on each side rather than simply asserting that supply overshoots.
Why announced capacity is not usable capacity
A third exhibit addresses the difference between curies produced and curies a programme can actually dose with, turning on a quality characteristic that varies by production route. This is the mechanism the extract uses to explain why headline capacity figures overstate what reaches patients.
Where the moat goes
The final exhibit asks what becomes defensible once volume alone stops conferring advantage, and sketches where the extract expects durable position to sit instead. It is the pivot from a supply thesis to a capability thesis, stated as direction rather than as a ranked answer.
A compressed read per stakeholder
The closing pages give a short read for each group with money or programmes exposed to the turn, covering what each should be watching and on what timescale. The extract keeps these to top-line positions; the full playbook is held back for the paid edition.
How it was built
A short public preview of a longer ProGen Search intelligence report. It carries the core thesis, four of the report's exhibits and a top-line stakeholder read, and it is explicit about what it leaves out: the full producer-route classification, the cost-per-curie model, the investor exposure scorecard and the complete stakeholder playbook. Markers run throughout the extract showing where the paid edition goes further, so a reader can see the boundary rather than guess at it. Positions are stated as of Q3 2026.
Written for investors holding or underwriting alpha production assets, radiopharmaceutical developers dependent on actinium-225 supply, and isotope producers deciding what to build.
Contents
- How to read this extract, and what it withholds
- Executive summary: the belief and its expiry date
- Exhibit: the announced capacity build-out
- Exhibit: the supply-versus-demand air-gap
- Exhibit: the purity split that decides usable supply
- Exhibit: where the moat goes when scarcity fades
- A compressed read for each stakeholder
- Methodology and disclaimer
Organisations referenced
Bristol Myers Squibb, RayzeBio, AstraZeneca, Fusion Pharmaceuticals, Novartis, Mariana Oncology
The full 16-page briefing is free. Tell us where to send it and it downloads immediately.
Peak Actinium: The Complete Analysis
This is a 16-page public extract. The full edition adds the producer-route classification, the cost-per-curie model, the investor exposure scorecard and the complete stakeholder playbook.
See the full report →